|
Immunoprecise Antibudies Ltd. (IPA) DCF تقييم |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
ImmunoPrecise Antibodies Ltd. (IPA) Bundle
اكتساب نظرة ثاقبة على تحليل التقييم المناعي للأجسام المضادة المناعية (IPA) باستخدام حاسبة DCF المتطورة! يأتي قالب Excel هذا مسبقًا مع بيانات حقيقية (IPA) ، مما يتيح لك ضبط التوقعات والافتراضات لحساب دقيق للقيمة الجوهرية لـ Immunoprecise Antibodies Ltd.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2021 |
AY2 2022 |
AY3 2023 |
AY4 2024 |
AY5 2025 |
FY1 2026 |
FY2 2027 |
FY3 2028 |
FY4 2029 |
FY5 2030 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.0 | 14.1 | 15.0 | 17.8 | 17.8 | 19.3 | 20.9 | 22.7 | 24.6 | 26.7 |
| Revenue Growth, % | 0 | 8.11 | 6.72 | 18.65 | 0.00815727 | 8.37 | 8.37 | 8.37 | 8.37 | 8.37 |
| EBITDA | -1.0 | -8.7 | -15.3 | -16.7 | -21.0 | -14.1 | -15.2 | -16.5 | -17.9 | -19.4 |
| EBITDA, % | -7.92 | -61.94 | -101.8 | -93.6 | -117.68 | -72.69 | -72.69 | -72.69 | -72.69 | -72.69 |
| Depreciation | 2.7 | 2.7 | 4.9 | 4.2 | 3.7 | 4.5 | 4.9 | 5.3 | 5.7 | 6.2 |
| Depreciation, % | 20.73 | 19.46 | 32.35 | 23.39 | 20.88 | 23.36 | 23.36 | 23.36 | 23.36 | 23.36 |
| EBIT | -3.7 | -11.5 | -20.2 | -20.9 | -24.7 | -15.9 | -17.2 | -18.6 | -20.2 | -21.9 |
| EBIT, % | -28.65 | -81.4 | -134.15 | -116.99 | -138.56 | -82.01 | -82.01 | -82.01 | -82.01 | -82.01 |
| Total Cash | 30.4 | 21.8 | 6.0 | 2.5 | 7.8 | 11.5 | 12.5 | 13.5 | 14.6 | 15.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.6 | 2.5 | 2.8 | 3.0 | 3.5 | 3.6 | 3.9 | 4.2 | 4.6 | 4.9 |
| Account Receivables, % | 20.25 | 17.6 | 18.77 | 16.59 | 19.6 | 18.56 | 18.56 | 18.56 | 18.56 | 18.56 |
| Inventories | .9 | 1.2 | 1.5 | 1.6 | 1.5 | 1.6 | 1.8 | 1.9 | 2.1 | 2.3 |
| Inventories, % | 6.72 | 8.34 | 9.97 | 8.72 | 8.54 | 8.46 | 8.46 | 8.46 | 8.46 | 8.46 |
| Accounts Payable | 1.0 | 2.8 | 1.8 | 3.0 | 3.8 | 3.0 | 3.3 | 3.5 | 3.8 | 4.2 |
| Accounts Payable, % | 7.51 | 20.23 | 12.02 | 16.61 | 21.55 | 15.58 | 15.58 | 15.58 | 15.58 | 15.58 |
| Capital Expenditure | -1.0 | -.9 | -1.1 | -1.0 | -.6 | -1.2 | -1.3 | -1.4 | -1.5 | -1.6 |
| Capital Expenditure, % | -7.97 | -6.49 | -7.23 | -5.7 | -3.26 | -6.13 | -6.13 | -6.13 | -6.13 | -6.13 |
| Tax Rate, % | 11.77 | 11.77 | 11.77 | 11.77 | 11.77 | 11.77 | 11.77 | 11.77 | 11.77 | 11.77 |
| EBITAT | -4.6 | -12.1 | -19.3 | -19.8 | -21.8 | -15.2 | -16.4 | -17.8 | -19.3 | -20.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -5.4 | -8.5 | -17.2 | -15.6 | -18.3 | -12.9 | -13.0 | -14.1 | -15.3 | -16.6 |
| WACC, % | 6.09 | 6.09 | 6.07 | 6.06 | 6.03 | 6.07 | 6.07 | 6.07 | 6.07 | 6.07 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -60.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -17 | |||||||||
| Terminal Value | -415 | |||||||||
| Present Terminal Value | -309 | |||||||||
| Enterprise Value | -369 | |||||||||
| Net Debt | 2 | |||||||||
| Equity Value | -371 | |||||||||
| Diluted Shares Outstanding, MM | 33 | |||||||||
| Equity Value Per Share | -11.13 |
What You Will Get
- Real IPA Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for ImmunoPrecise Antibodies Ltd. (IPA).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates tailored for IPA.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on ImmunoPrecise Antibodies Ltd.'s (IPA) fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to IPA.
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility for ImmunoPrecise Antibodies Ltd. (IPA).
Key Features
- Comprehensive Immunology Data: Access reliable pre-loaded historical performance metrics and future forecasts for ImmunoPrecise Antibodies Ltd. (IPA).
- Adjustable Research Parameters: Modify highlighted cells for critical factors like R&D expenses, market growth rates, and product margins.
- Real-Time Analytics: Automatic recalculations for DCF, Net Present Value (NPV), and revenue projections.
- Interactive Visualization Tools: User-friendly charts and summaries to effectively present your valuation outcomes.
- Designed for All Experience Levels: An intuitive layout tailored for researchers, investors, and industry experts.
How It Works
- Step 1: Download the prebuilt Excel template featuring ImmunoPrecise Antibodies Ltd. (IPA) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly observe the recalculated results, including ImmunoPrecise Antibodies Ltd.'s (IPA) intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the generated outputs.
Why Choose ImmunoPrecise Antibodies Ltd. (IPA)?
- Precision: Utilizes cutting-edge technology for accurate antibody development.
- Customization: Tailored solutions to meet specific research and therapeutic needs.
- Efficiency: Streamlined processes reduce time to market for critical discoveries.
- Expertise: Backed by a team of industry veterans with extensive experience.
- User-Centric: Designed for accessibility, catering to both seasoned scientists and newcomers.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive valuation models for analyzing ImmunoPrecise Antibodies Ltd. (IPA).
- Corporate Development Teams: Evaluate various valuation scenarios to inform strategic decisions.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in ImmunoPrecise Antibodies Ltd. (IPA).
- Students and Educators: Utilize real-world data to enhance learning in biotech financial modeling.
- Healthcare Enthusiasts: Gain insights into how biotech firms like ImmunoPrecise Antibodies Ltd. (IPA) are valued in the market.
What the Template Contains
- Pre-Filled DCF Model: ImmunoPrecise Antibodies Ltd.'s (IPA) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate ImmunoPrecise's profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.